EFFECTS OF GAMMA INTERFERON ON RELEASE OF TUMOR-NECROSIS-FACTOR-ALPHA FROM LIPOPOLYSACCHARIDE-TOLERANT HUMAN MONOCYTE-DERIVED MACROPHAGES

被引:29
作者
MATIC, M
SIMON, SR
机构
[1] SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794
[2] SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794
关键词
D O I
10.1128/IAI.60.9.3756-3762.1992
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
After an initial stimulation of human monocyte-derived macrophages with bacterial lipopolysaccharide (LPS), which produces substantial release of tumor necrosis factor-alpha (TNF-alpha), a subsequent exposure to LPS results in about an order-of-magnitude reduction in the levels of TNF-alpha released. We have shown that macrophages which have been stimulated with LPS and then maintained in culture without LPS for as long as 2 weeks do not regain their original capacity to secrete TNF-alpha upon a second LPS challenge. After 2 to 4 days in adherent culture, monocyte-derived macrophages which were not pretreated with LPS also experience a measurable decline in their capacity to release TNF-alpha in response to an initial LPS stimulation. When compared with these previously nonstimulated cells, however, the levels of TNF-alpha released by LPS-pretreated cells in response to a second LPS challenge decline by over 90% after 8 to 9 days in culture. Unstimulated cells spontaneously release barely detectable levels of TNF-alpha. In contrast to the release of TNF-alpha, unstimulated cells release significant levels of prostaglandin E2 continuously over time, and these levels are variably increased by no more than a factor of two in response to a single LPS stimulation. Prostaglandin E2 levels released by LPS-pretreated cells in response to a second LPS stimulation are much closer to the levels released by unstimulated cells. We have also demonstrated that gamma interferon (IFN-gamma) enhances TNF-alpha release from LPS-stimulated macrophages but not from phorbol myristate acetate-stimulated cells. Addition of IFN-gamma to macrophages either during the initial stimulation or during a second stimulation with LPS enhances levels of TNF-alpha released after the second LPS challenge. The greatest enhancement is observed when IFN-gamma is added during both exposures to LPS, but addition of IFN-gamma during only the initial LPS stimulation still results in marked enhancement of TNF-alpha release in response to a second stimulation with LPS 24 h later. If an interval of 2 days of culture in medium alone separates the first and second 24-h LPS stimulations, IFN-gamma enhances TNF-alpha release only when it is included during the second LPS exposure, indicating that, unlike the persistence of endotoxin tolerance, enhancement of TNF-alpha release by IFN-gamma is transient.
引用
收藏
页码:3756 / 3762
页数:7
相关论文
共 32 条
[1]   MOLECULAR TRANSDUCTIONAL MECHANISMS BY WHICH IFN-GAMMA AND OTHER SIGNALS REGULATE MACROPHAGE DEVELOPMENT [J].
ADAMS, DO ;
HAMILTON, TA .
IMMUNOLOGICAL REVIEWS, 1987, 97 :5-27
[2]  
AIYER RA, 1986, J IMMUNOL, V136, P3329
[3]   EFFECT OF GAMMA-INTERFERON ON CACHECTIN EXPRESSION BY MONONUCLEAR PHAGOCYTES - REVERSAL OF THE LPSD (ENDOTOXIN RESISTANCE) PHENOTYPE [J].
BEUTLER, B ;
TKACENKO, V ;
MILSARK, I ;
KROCHIN, N ;
CERAMI, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 164 (05) :1791-1796
[4]   THE BIOLOGY OF CACHECTIN/TNF - A PRIMARY MEDIATOR OF THE HOST RESPONSE [J].
BEUTLER, B ;
CERAMI, A .
ANNUAL REVIEW OF IMMUNOLOGY, 1989, 7 :625-655
[5]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[6]   ENDOTOXIN-INDUCED SERUM FACTOR THAT CAUSES NECROSIS OF TUMORS [J].
CARSWELL, EA ;
OLD, LJ ;
KASSEL, RL ;
GREEN, S ;
FIORE, N ;
WILLIAMSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (09) :3666-3670
[7]  
CHEDID L, 1971, MICROBIAL TOXINS, V5, P415
[8]   GAMMA-INTERFERON ENHANCES MACROPHAGE TRANSCRIPTION OF THE TUMOR-NECROSIS-FACTOR CACHECTIN, INTERLEUKIN-1, AND UROKINASE GENES, WHICH ARE CONTROLLED BY SHORT-LIVED REPRESSORS [J].
COLLART, MA ;
BELIN, D ;
VASSALLI, JD ;
DEKOSSODO, S ;
VASSALLI, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 164 (06) :2113-2118
[9]  
DOUGHERTY GJ, 1989, HUMAN MONOCYTES, P49
[10]  
FINBLOO MDS, 1985, J IMMUNOL, V135, P3000